25 XP   0   0   10

Laboratorios Richmond SACIF
Buy, Hold or Sell?

Let's analyse Laboratorios Richmond SACIF together

PenkeI guess you are interested in Laboratorios Richmond SACIF. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Laboratorios Richmond SACIF. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Laboratorios Richmond SACIF

I send you an email if I find something interesting about Laboratorios Richmond SACIF.

Quick analysis of Laboratorios Richmond SACIF (30 sec.)










What can you expect buying and holding a share of Laboratorios Richmond SACIF? (30 sec.)

How much money do you get?

How much money do you get?
ARS0.00
When do you have the money?
1 year
How often do you get paid?
52.5%

What is your share worth?

Current worth
ARS217.82
Expected worth in 1 year
ARS321.02
How sure are you?
85.0%

+ What do you gain per year?

Total Gains per Share
ARS107.20
Return On Investment
13.4%

For what price can you sell your share?

Current Price per Share
ARS802.50
Expected price per share
ARS595.50 - ARS1,235
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Laboratorios Richmond SACIF (5 min.)




Live pricePrice per Share (EOD)

ARS802.50

Intrinsic Value Per Share

ARS-3,004.99 - ARS-3,579.70

Total Value Per Share

ARS-2,787.18 - ARS-3,361.89

2. Growth of Laboratorios Richmond SACIF (5 min.)




Is Laboratorios Richmond SACIF growing?

Current yearPrevious yearGrowGrow %
How rich?$21.1m$8.6m$7.7m47.3%

How much money is Laboratorios Richmond SACIF making?

Current yearPrevious yearGrowGrow %
Making money-$1m$364.5k-$1.4m-134.7%
Net Profit Margin-16.4%5.3%--

How much money comes from the company's main activities?

3. Financial Health of Laboratorios Richmond SACIF (5 min.)




3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Laboratorios Richmond SACIF? (5 min.)

Welcome investor! Laboratorios Richmond SACIF's management wants to use your money to grow the business. In return you get a share of Laboratorios Richmond SACIF.

What can you expect buying and holding a share of Laboratorios Richmond SACIF?

First you should know what it really means to hold a share of Laboratorios Richmond SACIF. And how you can make/lose money.

Speculation

The Price per Share of Laboratorios Richmond SACIF is ARS802.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Laboratorios Richmond SACIF.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Laboratorios Richmond SACIF, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ARS217.82. Based on the TTM, the Book Value Change Per Share is ARS25.80 per quarter. Based on the YOY, the Book Value Change Per Share is ARS15.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ARS1.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Laboratorios Richmond SACIF.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ARS% of Price per ShareARS% of Price per ShareARS% of Price per ShareARS% of Price per ShareARS% of Price per Share
Usd Eps-0.030.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share0.050.0%0.030.0%0.020.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.050.0%0.030.0%0.020.0%0.010.0%0.010.0%
Usd Price Per Share0.62-0.54-0.30-0.25-0.13-
Price to Earnings Ratio-5.09-14.09--9.57--5.94--2.04-
Price-to-Total Gains Ratio13.65-18.11-15.67-26.53-22.15-
Price to Book Ratio2.36-2.71-2.88-3.13-1.62-
Price-to-Total Gains Ratio13.65-18.11-15.67-26.53-22.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.963
Number of shares1038
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.01
Usd Total Gains Per Share0.030.01
Gains per Quarter (1038 shares)33.3810.79
Gains per Year (1038 shares)133.5343.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1512912434033
21025725858176
3153863928121119
42051452611162162
52564366014202205
63077179416243248
73590092819283291
8401028106222323334
9451157119625364377
10501286133027404420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%5.07.00.041.7%9.011.00.045.0%24.011.05.060.0%26.011.06.060.5%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%32.08.00.080.0%33.09.01.076.7%
Dividend per Share1.00.03.025.0%9.00.03.075.0%11.00.09.055.0%21.00.019.052.5%22.00.021.051.2%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%34.06.00.085.0%35.07.01.081.4%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Laboratorios Richmond SACIF

About Laboratorios Richmond SACIF

Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East. Laboratorios Richmond S.A.C.I.F. was founded in 1935 and is headquartered in Buenos Aires, Argentina.

Fundamental data was last updated by Penke on 2024-02-19 22:08:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Laboratorios Richmond SACIF.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Laboratorios Richmond SACIF earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -36.4% means that $-0.36 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Laboratorios Richmond SACIF:

  • The MRQ is -36.4%. The company is making a huge loss. -2
  • The TTM is -16.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-36.4%TTM-16.4%-20.1%
TTM-16.4%YOY5.3%-21.7%
TTM-16.4%5Y-2.7%-13.7%
5Y-2.7%10Y0.9%-3.5%
1.1.2. Return on Assets

Shows how efficient Laboratorios Richmond SACIF is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.6% Return on Assets means that Laboratorios Richmond SACIF generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Laboratorios Richmond SACIF:

  • The MRQ is -2.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.6%TTM-1.4%-1.3%
TTM-1.4%YOY1.1%-2.5%
TTM-1.4%5Y0.0%-1.3%
5Y0.0%10Y0.6%-0.7%
1.1.3. Return on Equity

Shows how efficient Laboratorios Richmond SACIF is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • -11.8% Return on Equity means Laboratorios Richmond SACIF generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Laboratorios Richmond SACIF:

  • The MRQ is -11.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-5.9%-5.9%
TTM-5.9%YOY5.2%-11.1%
TTM-5.9%5Y-0.2%-5.7%
5Y-0.2%10Y2.7%-2.9%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Laboratorios Richmond SACIF.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Laboratorios Richmond SACIF is operating .

  • Measures how much profit Laboratorios Richmond SACIF makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Laboratorios Richmond SACIF:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.3%-10.3%
TTM10.3%YOY13.4%-3.1%
TTM10.3%5Y13.1%-2.9%
5Y13.1%10Y6.6%+6.6%
1.2.2. Operating Ratio

Measures how efficient Laboratorios Richmond SACIF is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.88 means that the operating costs are $1.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Laboratorios Richmond SACIF:

  • The MRQ is 1.879. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.485. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.879TTM1.485+0.394
TTM1.485YOY1.475+0.010
TTM1.4855Y1.424+0.061
5Y1.42410Y0.943+0.481
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Laboratorios Richmond SACIF.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Laboratorios Richmond SACIF is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.07 means the company has $1.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Laboratorios Richmond SACIF:

  • The MRQ is 1.067. The company is just able to pay all its short-term debts.
  • The TTM is 1.306. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.067TTM1.306-0.239
TTM1.306YOY1.586-0.280
TTM1.3065Y1.394-0.088
5Y1.39410Y0.697+0.697
1.3.2. Quick Ratio

Measures if Laboratorios Richmond SACIF is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.36 means the company can pay off $0.36 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Laboratorios Richmond SACIF:

  • The MRQ is 0.359. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.599. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.359TTM0.599-0.240
TTM0.599YOY0.747-0.148
TTM0.5995Y0.633-0.034
5Y0.63310Y0.685-0.052
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Laboratorios Richmond SACIF.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Laboratorios Richmond SACIF assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Laboratorios Richmond SACIF to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.77 means that Laboratorios Richmond SACIF assets are financed with 77.3% credit (debt) and the remaining percentage (100% - 77.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Laboratorios Richmond SACIF:

  • The MRQ is 0.773. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.753. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.773TTM0.753+0.020
TTM0.753YOY0.754-0.001
TTM0.7535Y0.673+0.080
5Y0.67310Y0.708-0.035
1.4.2. Debt to Equity Ratio

Measures if Laboratorios Richmond SACIF is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 344.3% means that company has $3.44 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Laboratorios Richmond SACIF:

  • The MRQ is 3.443. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.098. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.443TTM3.098+0.345
TTM3.098YOY3.144-0.046
TTM3.0985Y2.337+0.761
5Y2.33710Y2.797-0.460
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Laboratorios Richmond SACIF

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Laboratorios Richmond SACIF generates.

  • Above 15 is considered overpriced but always compare Laboratorios Richmond SACIF to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -5.09 means the investor is paying $-5.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Laboratorios Richmond SACIF:

  • The EOD is -7.926. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.086. Based on the earnings, the company is expensive. -2
  • The TTM is 14.090. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-7.926MRQ-5.086-2.839
MRQ-5.086TTM14.090-19.176
TTM14.090YOY-9.575+23.664
TTM14.0905Y-5.936+20.026
5Y-5.93610Y-2.038-3.898
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Laboratorios Richmond SACIF:

  • The EOD is -3.464. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.223. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.918. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.464MRQ-2.223-1.241
MRQ-2.223TTM-3.918+1.695
TTM-3.918YOY-2.218-1.700
TTM-3.9185Y2.045-5.963
5Y2.04510Y0.881+1.164
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Laboratorios Richmond SACIF is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Laboratorios Richmond SACIF:

  • The EOD is 3.684. Based on the equity, the company is fair priced.
  • The MRQ is 2.364. Based on the equity, the company is underpriced. +1
  • The TTM is 2.713. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.684MRQ2.364+1.320
MRQ2.364TTM2.713-0.348
TTM2.713YOY2.885-0.172
TTM2.7135Y3.129-0.416
5Y3.12910Y1.623+1.507
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Laboratorios Richmond SACIF compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--37.73325.802+46%15.248+147%8.114+365%5.298+612%
Book Value Per Share--217.815169.794+28%89.435+144%73.563+196%45.114+383%
Current Ratio--1.0671.306-18%1.586-33%1.394-23%0.697+53%
Debt To Asset Ratio--0.7730.753+3%0.754+3%0.673+15%0.708+9%
Debt To Equity Ratio--3.4433.098+11%3.144+9%2.337+47%2.797+23%
Dividend Per Share---0.997-100%1.069-100%0.552-100%0.579-100%
Eps---25.313-10.787-57%1.895-1436%-2.175-91%-0.752-97%
Free Cash Flow Per Share---57.915-36.494-37%-34.322-41%-15.872-73%-10.220-82%
Free Cash Flow To Equity Per Share---57.915-15.599-73%-15.106-74%-6.823-88%-2.421-96%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.875+14%
Intrinsic Value_10Y_max---3579.705--------
Intrinsic Value_10Y_min---3004.992--------
Intrinsic Value_1Y_max---131.958--------
Intrinsic Value_1Y_min---129.482--------
Intrinsic Value_3Y_max---569.294--------
Intrinsic Value_3Y_min---540.006--------
Intrinsic Value_5Y_max---1214.976--------
Intrinsic Value_5Y_min---1112.836--------
Market Cap11369178000.000-266%41587015805.00036620799354.500+14%20430126211.000+104%16865298513.713+147%8474513332.856+391%
Net Profit Margin---0.364-0.164-55%0.053-789%-0.027-93%0.009-4326%
Operating Margin---0.103-100%0.134-100%0.131-100%0.066-100%
Operating Ratio--1.8791.485+27%1.475+27%1.424+32%0.943+99%
Pb Ratio3.684+36%2.3642.713-13%2.885-18%3.129-24%1.623+46%
Pe Ratio-7.926-56%-5.08614.090-136%-9.575+88%-5.936+17%-2.038-60%
Price Per Share802.500+36%515.000453.500+14%253.000+104%210.353+145%108.131+376%
Price To Free Cash Flow Ratio-3.464-56%-2.223-3.918+76%-2.2180%2.045-209%0.881-352%
Price To Total Gains Ratio21.268+36%13.64918.106-25%15.671-13%26.528-49%22.146-38%
Quick Ratio--0.3590.599-40%0.747-52%0.633-43%0.685-48%
Return On Assets---0.026-0.014-48%0.011-331%0.000-98%0.006-532%
Return On Equity---0.118-0.059-50%0.052-326%-0.002-98%0.027-539%
Total Gains Per Share--37.73326.799+41%16.317+131%8.665+335%5.878+542%
Usd Book Value--21106708.78416453346.383+28%8666402.765+144%6815079.223+210%3549201.921+495%
Usd Book Value Change Per Share--0.0450.031+46%0.018+147%0.010+365%0.006+612%
Usd Book Value Per Share--0.2610.204+28%0.107+144%0.088+196%0.054+383%
Usd Dividend Per Share---0.001-100%0.001-100%0.001-100%0.001-100%
Usd Eps---0.030-0.013-57%0.002-1436%-0.003-91%-0.001-97%
Usd Free Cash Flow---5612107.333-3536331.549-37%-3325867.718-41%-1431372.628-74%-711077.645-87%
Usd Free Cash Flow Per Share---0.069-0.044-37%-0.041-41%-0.019-73%-0.012-82%
Usd Free Cash Flow To Equity Per Share---0.069-0.019-73%-0.018-74%-0.008-88%-0.003-96%
Usd Market Cap13643013.600-266%49904418.96643944959.225+14%24516151.453+104%20238358.216+147%10169415.999+391%
Usd Price Per Share0.963+36%0.6180.544+14%0.304+104%0.252+145%0.130+376%
Usd Profit---2452904.982-1050574.840-57%364551.129-773%-117673.647-95%-53132.150-98%
Usd Revenue--6730290.0256248125.292+8%5433487.818+24%3451556.538+95%1839490.830+266%
Usd Total Gains Per Share--0.0450.032+41%0.020+131%0.010+335%0.007+542%
 EOD+4 -4MRQTTM+13 -22YOY+13 -225Y+13 -2210Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Laboratorios Richmond SACIF based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.926
Price to Book Ratio (EOD)Between0-13.684
Net Profit Margin (MRQ)Greater than0-0.364
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.359
Current Ratio (MRQ)Greater than11.067
Debt to Asset Ratio (MRQ)Less than10.773
Debt to Equity Ratio (MRQ)Less than13.443
Return on Equity (MRQ)Greater than0.15-0.118
Return on Assets (MRQ)Greater than0.05-0.026
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Laboratorios Richmond SACIF based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.928
Ma 20Greater thanMa 50952.350
Ma 50Greater thanMa 100878.720
Ma 100Greater thanMa 200771.615
OpenGreater thanClose808.000
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Retained Earnings  2,654,861-219,4612,435,400-2,161,748273,6522,510,4092,784,061-6,022,170-3,238,108
Operating Income  108,4561,316,4701,424,926-816,607608,319-540,25568,064-981,825-913,762



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in ARS. All numbers in thousands.

Summary
Total Assets77,434,627
Total Liabilities59,845,703
Total Stockholder Equity17,383,521
 As reported
Total Liabilities 59,845,703
Total Stockholder Equity+ 17,383,521
Total Assets = 77,434,627

Assets

Total Assets77,434,627
Total Current Assets19,146,342
Long-term Assets58,288,285
Total Current Assets
Cash And Cash Equivalents 400,806
Short-term Investments 213,093
Net Receivables 6,230,839
Inventory 8,934,662
Total Current Assets  (as reported)19,146,342
Total Current Assets  (calculated)15,779,400
+/- 3,366,942
Long-term Assets
Property Plant Equipment 47,109,824
Goodwill 2,058,835
Intangible Assets 7,982,542
Long-term Assets  (as reported)58,288,285
Long-term Assets  (calculated)57,151,201
+/- 1,137,084

Liabilities & Shareholders' Equity

Total Current Liabilities17,945,621
Long-term Liabilities41,900,082
Total Stockholder Equity17,383,521
Total Current Liabilities
Short Long Term Debt 5,790,879
Accounts payable 10,339,408
Other Current Liabilities 73
Total Current Liabilities  (as reported)17,945,621
Total Current Liabilities  (calculated)16,130,360
+/- 1,815,261
Long-term Liabilities
Long term Debt 3,908,865
Capital Lease Obligations Min Short Term Debt216,890
Long-term Liabilities Other 34,895
Long-term Liabilities  (as reported)41,900,082
Long-term Liabilities  (calculated)4,160,650
+/- 37,739,432
Total Stockholder Equity
Total Stockholder Equity (as reported)17,383,521
Total Stockholder Equity (calculated)0
+/- 17,383,521
Other
Capital Stock4,621,697
Common Stock Shares Outstanding 80,751
Net Debt 9,298,938
Net Invested Capital 27,083,265
Net Working Capital 1,200,721
Property Plant and Equipment Gross 53,942,232



Balance Sheet

Currency in ARS. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-312010-12-312009-12-312008-12-312008-09-302007-09-302006-09-30
> Total Assets 
56,356
77,583
100,634
107,007
127,840
135,779
159,025
270,955
276,743
276,743
290,686
287,372
315,091
323,549
357,608
385,658
387,299
391,705
400,815
532,834
556,555
640,283
724,917
861,132
726,253
779,149
912,391
1,552,641
1,637,185
1,821,701
2,402,981
2,705,186
2,805,766
2,948,371
3,807,181
5,134,618
5,260,627
5,845,090
6,986,402
8,133,335
9,254,840
12,165,119
24,167,525
25,693,158
26,062,569
30,899,929
33,553,373
40,720,110
47,570,398
58,907,378
77,434,627
77,434,62758,907,37847,570,39840,720,11033,553,37330,899,92926,062,56925,693,15824,167,52512,165,1199,254,8408,133,3356,986,4025,845,0905,260,6275,134,6183,807,1812,948,3712,805,7662,705,1862,402,9811,821,7011,637,1851,552,641912,391779,149726,253861,132724,917640,283556,555532,834400,815391,705387,299385,658357,608323,549315,091287,372290,686276,743276,743270,955159,025135,779127,840107,007100,63477,58356,356
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,967,306
1,914,169
1,894,278
2,571,194
3,287,659
3,263,874
3,591,461
4,519,380
5,371,511
5,406,240
7,750,533
10,771,693
15,434,862
11,898,535
13,723,575
12,314,790
14,040,135
14,035,121
16,163,176
19,146,342
19,146,34216,163,17614,035,12114,040,13512,314,79013,723,57511,898,53515,434,86210,771,6937,750,5335,406,2405,371,5114,519,3803,591,4613,263,8743,287,6592,571,1941,894,2781,914,1691,967,3060000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
501,119
347,465
258,089
350,686
217,146
310,788
500,976
315,168
493,831
516,623
404,284
1,597,793
4,666,788
2,223,395
752,939
1,625,507
1,255,852
805,126
1,103,850
400,806
400,8061,103,850805,1261,255,8521,625,507752,9392,223,3954,666,7881,597,793404,284516,623493,831315,168500,976310,788217,146350,686258,089347,465501,1190000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
481
799
1,148
3,668
1,720
1,188
1,085
357,776
345,707
347,005
532,356
85,949
2,693,158
1,815,837
1,778,922
1,297,585
1,433,968
745,570
188,186
213,093
213,093188,186745,5701,433,9681,297,5851,778,9221,815,8372,693,15885,949532,356347,005345,707357,7761,0851,1881,7203,6681,1487994810000000000000000000000000000000
       Net Receivables 
16,278
24,723
24,876
27,233
31,007
35,816
46,019
96,359
105,744
105,744
114,664
111,643
126,968
134,815
156,568
192,546
180,550
185,857
173,047
267,087
262,666
267,879
311,128
498,253
338,047
329,962
406,844
512,300
653,201
690,781
885,401
785,003
616,057
678,506
958,190
1,959,409
1,852,293
1,672,216
2,159,626
2,936,487
1,925,213
2,691,864
2,496,087
4,004,511
3,296,744
6,481,812
3,987,176
5,778,523
6,145,442
7,215,143
6,230,839
6,230,8397,215,1436,145,4425,778,5233,987,1766,481,8123,296,7444,004,5112,496,0872,691,8641,925,2132,936,4872,159,6261,672,2161,852,2931,959,409958,190678,506616,057785,003885,401690,781653,201512,300406,844329,962338,047498,253311,128267,879262,666267,087173,047185,857180,550192,546156,568134,815126,968111,643114,664105,744105,74496,35946,01935,81631,00727,23324,87624,72316,278
       Other Current Assets 
918
888
15,252
16,553
13,310
953
606
498
0
0
0
0
0
0
0
0
0
0
0
4,546
18,756
9,874
14,311
14,666
11,873
12,404
24,376
12,994
28,038
32,646
20,857
150,080
180,388
124,871
172,835
178,477
197,338
248,894
421,935
287,748
546,618
1,191,245
372,305
437,161
293,088
296,553
427,687
531,306
634,040
439,866
0
0439,866634,040531,306427,687296,553293,088437,161372,3051,191,245546,618287,748421,935248,894197,338178,477172,835124,871180,388150,08020,85732,64628,03812,99424,37612,40411,87314,66614,3119,87418,7564,5460000000000049860695313,31016,55315,252888918
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
1,846,959
1,996,753
2,253,630
2,467,021
3,168,386
3,848,600
4,414,586
13,395,832
10,258,296
14,164,034
17,176,354
21,238,583
26,679,974
33,535,276
42,744,202
58,288,285
58,288,28542,744,20233,535,27626,679,97421,238,58317,176,35414,164,03410,258,29613,395,8324,414,5863,848,6003,168,3862,467,0212,253,6301,996,7531,846,9591,235,9871,054,093891,59700000000000000000000000000000000
       Property Plant Equipment 
13,126
20,344
22,083
22,179
22,918
37,995
44,800
52,499
0
0
0
52,549
52,428
0
54,516
54,525
53,702
54,699
53,642
55,316
55,560
55,322
56,996
58,306
67,184
70,593
71,867
91,973
91,649
96,152
198,977
383,959
472,937
569,658
671,096
1,196,276
1,250,129
1,347,306
1,429,438
2,015,013
2,337,935
2,725,498
3,046,123
7,976,095
11,448,040
13,993,911
17,327,083
21,793,923
27,164,197
34,403,259
47,109,824
47,109,82434,403,25927,164,19721,793,92317,327,08313,993,91111,448,0407,976,0953,046,1232,725,4982,337,9352,015,0131,429,4381,347,3061,250,1291,196,276671,096569,658472,937383,959198,97796,15291,64991,97371,86770,59367,18458,30656,99655,32255,56055,31653,64254,69953,70254,52554,516052,42852,54900052,49944,80037,99522,91822,17922,08320,34413,126
       Goodwill 
0
0
0
0
0
0
0
40,438
0
0
0
31,420
30,973
0
30,079
29,632
29,184
28,737
28,290
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,248
32,609
33,121
143,669
178,636
193,533
221,859
245,929
287,113
304,512
328,063
300,277
409,657
449,661
486,155
531,171
610,307
712,137
864,545
1,017,397
1,233,327
1,525,164
2,058,835
2,058,8351,525,1641,233,3271,017,397864,545712,137610,307531,171486,155449,661409,657300,277328,063304,512287,113245,929221,859193,533178,636143,66933,12132,60932,24832,33939,78331,42031,42031,42031,42031,42031,42031,42028,29028,73729,18429,63230,079030,97331,42000040,4380000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,692
4,101
5,355
5,500
4,218
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004,2185,5005,3554,10111,6920000000000000000000000000000000
       Intangible Assets 
311
457
1,622
691
679
543
147
40,625
5,964
5,964
6,174
31,420
30,973
6,788
30,079
29,632
29,184
28,737
28,771
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,376
32,821
33,913
3,200
188,206
240,895
288,322
335,738
379,915
421,531
508,649
623,643
804,240
975,114
1,128,651
1,462,932
1,801,479
2,120,136
2,657,786
3,335,674
4,211,231
5,676,420
7,982,542
7,982,5425,676,4204,211,2313,335,6742,657,7862,120,1361,801,4791,462,9321,128,651975,114804,240623,643508,649421,531379,915335,738288,322240,895188,2063,20033,91332,82132,37632,33939,78331,42031,42031,42031,42031,42031,42031,42028,77128,73729,18429,63230,0796,78830,97331,4206,1745,9645,96440,6251475436796911,622457311
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,235,9871,054,093891,59700000000000000000000000000000000
> Total Liabilities 
48,610
64,334
71,342
68,621
74,108
90,962
108,921
178,942
185,468
185,468
207,433
196,336
235,531
243,608
274,160
292,642
299,363
300,866
303,726
436,712
460,578
540,743
605,060
671,672
549,419
625,695
715,969
864,588
911,607
1,130,640
1,616,125
1,594,256
1,669,514
1,731,410
2,369,968
3,034,658
3,051,279
3,443,970
4,275,481
4,752,830
5,500,623
8,099,865
19,838,051
20,317,526
19,620,716
23,084,085
24,298,693
30,502,686
35,074,179
44,365,456
59,845,703
59,845,70344,365,45635,074,17930,502,68624,298,69323,084,08519,620,71620,317,52619,838,0518,099,8655,500,6234,752,8304,275,4813,443,9703,051,2793,034,6582,369,9681,731,4101,669,5141,594,2561,616,1251,130,640911,607864,588715,969625,695549,419671,672605,060540,743460,578436,712303,726300,866299,363292,642274,160243,608235,531196,336207,433185,468185,468178,942108,92190,96274,10868,62171,34264,33448,610
   > Total Current Liabilities 
36,242
32,065
51,411
48,157
50,443
49,927
70,886
132,790
144,643
144,643
164,239
153,556
182,401
186,583
218,576
239,846
243,496
240,821
222,613
337,703
354,829
390,143
455,045
546,952
425,365
516,202
634,249
748,417
780,462
954,980
1,327,483
1,250,101
1,267,508
1,380,095
2,005,622
2,475,950
2,480,757
2,820,832
3,522,630
3,550,319
3,695,913
5,913,989
9,805,072
9,326,184
7,329,125
9,279,231
7,768,059
9,034,122
10,087,341
13,338,288
17,945,621
17,945,62113,338,28810,087,3419,034,1227,768,0599,279,2317,329,1259,326,1849,805,0725,913,9893,695,9133,550,3193,522,6302,820,8322,480,7572,475,9502,005,6221,380,0951,267,5081,250,1011,327,483954,980780,462748,417634,249516,202425,365546,952455,045390,143354,829337,703222,613240,821243,496239,846218,576186,583182,401153,556164,239144,643144,643132,79070,88649,92750,44348,15751,41132,06536,242
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000346,659449,337340,886341,545302,3300000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
325,998
566,163
987,993
659,873
632,373
1,871,833
2,090,837
1,788,036
1,550,121
2,146,245
2,337,427
2,858,241
3,710,779
5,106,602
5,790,879
5,790,8795,106,6023,710,7792,858,2412,337,4272,146,2451,550,1211,788,0362,090,8371,871,833632,373659,873987,993566,163325,998346,659449,337340,886341,545302,3300000000000000000000000000000000
       Accounts payable 
33,502
27,105
43,601
40,415
36,735
25,200
36,272
72,066
63,494
63,494
68,286
55,509
82,352
79,388
100,744
102,671
116,583
109,532
105,153
161,772
177,376
189,468
195,173
225,076
190,964
280,531
365,272
375,389
373,387
530,682
833,245
857,549
854,992
967,806
1,428,534
1,861,857
1,905,383
2,028,514
2,226,285
2,360,382
2,721,935
3,739,832
6,263,583
5,724,387
4,051,809
5,322,342
4,050,455
4,786,692
5,354,720
7,007,160
10,339,408
10,339,4087,007,1605,354,7204,786,6924,050,4555,322,3424,051,8095,724,3876,263,5833,739,8322,721,9352,360,3822,226,2852,028,5141,905,3831,861,8571,428,534967,806854,992857,549833,245530,682373,387375,389365,272280,531190,964225,076195,173189,468177,376161,772105,153109,532116,583102,671100,74479,38882,35255,50968,28663,49463,49472,06636,27225,20036,73540,41543,60127,10533,502
       Other Current Liabilities 
540
2,308
3,001
2,862
2,442
4,252
7,325
15,221
20,912
20,912
17,560
11,919
13,022
14,132
15,077
19,240
18,811
24,886
20,877
36,280
51,298
52,763
59,489
114,519
63,502
78,660
68,825
100,418
102,432
70,939
119,724
22,193
8
8,504
11,529
51,563
78,576
108,638
147,153
159,442
73,729
83,902
92,093
314,716
326,170
453,281
182,535
172,717
110,677
180,704
73
73180,704110,677172,717182,535453,281326,170314,71692,09383,90273,729159,442147,153108,63878,57651,56311,5298,504822,193119,72470,939102,432100,41868,82578,66063,502114,51959,48952,76351,29836,28020,87724,88618,81119,24015,07714,13213,02211,91917,56020,91220,91215,2217,3254,2522,4422,8623,0012,308540
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
402,006
351,315
364,345
558,708
570,522
623,138
752,851
1,486,170
1,804,710
2,185,876
10,032,979
10,991,342
12,291,590
13,804,853
16,530,634
21,468,563
24,986,838
31,027,168
41,900,082
41,900,08231,027,16824,986,83821,468,56316,530,63413,804,85312,291,59010,991,34210,032,9792,185,8761,804,7101,486,170752,851623,138570,522558,708364,345351,315402,00600000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-302,330
-341,545
-340,886
-449,337
-315,521
73,061
72,111
68,712
31,771
5,854
18
25,484
146,125
147,144
154,524
170,176
190,451
207,659
175,324
216,890
216,890175,324207,659190,451170,176154,524147,144146,12525,484185,85431,77168,71272,11173,061-315,521-449,337-340,886-341,545-302,3300000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,408
68,459
93,506
44,112
6,437
7,036
7,598
13,238
22,032
22,925
11,825
12,302
13,297
12,503
14,712
17,696
20,861
25,630
34,895
34,89525,63020,86117,69614,71212,50313,29712,30211,82522,92522,03213,2387,5987,0366,43744,11293,50668,45969,40800000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140,103
183,662
235,836
282,143
327,755
372,981
414,059
501,529
647,600
796,149
967,297
1,120,985
1,454,967
1,792,758
2,107,607
2,632,992
3,261,103
4,087,482
5,451,190
0
05,451,1904,087,4823,261,1032,632,9922,107,6071,792,7581,454,9671,120,985967,297796,149647,600501,529414,059372,981327,755282,143235,836183,662140,1030000000000000000000000000000000
> Total Stockholder Equity
7,746
13,245
29,288
38,381
53,727
44,815
50,110
91,953
91,274
91,274
83,253
91,036
79,560
79,941
83,447
93,016
87,937
90,839
97,089
96,121
95,976
99,540
119,858
189,460
176,834
153,454
196,421
688,053
708,993
667,279
709,077
1,051,302
1,105,404
1,181,850
1,389,902
2,050,207
2,155,494
2,347,810
2,655,308
3,380,506
3,681,875
3,990,315
4,245,571
5,293,621
6,350,584
7,714,700
9,144,791
10,090,176
12,349,198
14,377,543
17,383,521
17,383,52114,377,54312,349,19810,090,1769,144,7917,714,7006,350,5845,293,6214,245,5713,990,3153,681,8753,380,5062,655,3082,347,8102,155,4942,050,2071,389,9021,181,8501,105,4041,051,302709,077667,279708,993688,053196,421153,454176,834189,460119,85899,54095,97696,12197,08990,83987,93793,01683,44779,94179,56091,03683,25391,27491,27491,95350,11044,81553,72738,38129,28813,2457,746
   Common Stock
133
2,822
2,822
3,642
3,642
27,254
27,254
27,254
66,584
66,584
66,584
27,254
27,254
66,584
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
66,584
66,584
66,584
80,752
80,752
80,752
80,752
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
0
080,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75180,75280,75280,75280,75266,58466,58466,58427,25427,25427,25427,25427,25427,25427,25427,25427,25427,25466,58427,25427,25466,58466,58466,58427,25427,25427,2543,6423,6422,8222,822133
   Retained Earnings 
7,429
10,423
10,966
12,265
14,519
17,561
22,856
25,369
24,690
24,690
16,669
24,452
12,975
13,356
16,863
26,432
21,352
24,255
30,504
29,537
29,392
32,956
53,273
122,876
110,250
86,870
103,289
115,573
135,917
83,834
89,372
-71,520
-338,266
-368,480
-388,342
6,420
-12,206
36,813
172,675
494,981
459,822
545,360
518,403
1,278,729
1,708,081
2,318,863
2,654,861
2,435,400
273,652
2,784,061
-3,238,108
-3,238,1082,784,061273,6522,435,4002,654,8612,318,8631,708,0811,278,729518,403545,360459,822494,981172,67536,813-12,2066,420-388,342-368,480-338,266-71,52089,37283,834135,917115,573103,28986,870110,250122,87653,27332,95629,39229,53730,50424,25521,35226,43216,86313,35612,97524,45216,66924,69024,69025,36922,85617,56114,51912,26510,96610,4237,429
   Capital Surplus 000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316,146
361,582
373,046
463,986
846,328
883,139
961,737
1,036,270
1,284,478
1,424,085
1,458,905
1,564,253
1,639,383
1,898,233
2,190,727
2,598,195
3,103,994
3,787,605
4,777,230
0
04,777,2303,787,6053,103,9942,598,1952,190,7271,898,2331,639,3831,564,2531,458,9051,424,0851,284,4781,036,270961,737883,139846,328463,986373,046361,582316,1460000000000000000000000000000000



Balance Sheet

Currency in ARS. All numbers in thousands.




Cash Flow

Currency in ARS. All numbers in thousands.